Webcast Link: Available on the News & Events page of the I-Mab website The webcast of the event will be accessible from News & Events page of the I-Mab website for 90 days. I-Mab (NASDAQ: IMAB) is a U ...

** When you buy products through the links on our site, we may earn a commission that supports NRA's mission to protect, preserve and defend the Second Amendment. ** My father was a World War II ...

Roblox is an extremely popular online gaming platform. Far from giving signs that it is shutting down, last year, the company announced a series of upgrades. In fact, on Aug. 22, the company's stock ...

MAINZ, Germany & MUNICH--(BUSINESS WIRE)--BioNTech AG, a rapidly growing biotechnology company developing precise and individualized immunotherapies for the treatment of cancer and the prevention of ...

ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the ...

A new federal complaint accuses the gaming giant of ignoring warnings about exploitative content and failing to protect children Gabby Jones/Bloomberg/Getty A new filing describes a 10-year-old girl ...

Editor's note: This article contains descriptions and an image of hate speech found on the Roblox servers and might be triggering to some readers. In Roblox, one of the world's largest online gaming ...

The latest price target for I-MAB (NASDAQ:IMAB) was reported by Leerink Partners on October 3, 2025. The analyst firm set a price target for $9.00 expecting IMAB to rise to within 12 months (a ...

Rumors have been swirling that popular online gaming platform Roblox is shutting down. Roblox allows users to make a virtual universe and participate in millions of games and interactive environments.

I-Mab (NASDAQ:IMAB) said on Thursday that it has signed an agreement to acquire Bridge Health Biotech in a bid to gain upstream rights to CLDN18.2 parental antibody used in its experimental cancer ...

I-Mab has completed enrollment ahead of schedule in the first cohort of its Phase 1b dose expansion study, which evaluates the bispecific antibody givastomig for treating gastric cancer. The study ...

Upcoming anticipated milestones for givastomig (CLDN18.2 x 4-1BB bispecific), prioritized to be I-Mab’s lead program in January 2025: 1H 2026: Presentation of data from givastomig dose expansion ...